Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo.

Disterer P, Al-Shawi R, Ellmerich S, Waddington SN, Owen JS, Simons JP, Khoo B.

Mol Ther. 2013 Mar;21(3):602-9. doi: 10.1038/mt.2012.264. Epub 2013 Jan 15.

2.
3.
4.

Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.

Bell DA, Hooper AJ, Watts GF, Burnett JR.

Vasc Health Risk Manag. 2012;8:651-9. doi: 10.2147/VHRM.S28581. Epub 2012 Nov 28. Review.

5.

The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.

Jensen HK.

Dan Med Bull. 2002 Nov;49(4):318-45. Review.

PMID:
12553167
6.

ApoB metabolism in familial hypercholesterolemia. Inconsistencies with the LDL receptor paradigm.

Fisher WR, Zech LA, Stacpoole PW.

Arterioscler Thromb. 1994 Apr;14(4):501-10. Review.

PMID:
8148348
7.

Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia.

Gaffney D, Forster L, Caslake MJ, Bedford D, Stewart JP, Stewart G, Wieringa G, Dominiczak M, Miller JP, Packard CJ.

Atherosclerosis. 2002 May;162(1):33-43.

PMID:
11947895
8.

Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study.

Cummings MH, Watts GF, Umpleby M, Hennessy TR, Quiney JR, Sönksen PH.

Atherosclerosis. 1995 Feb;113(1):79-89.

PMID:
7755658
9.
10.

A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet.

Powell-Braxton L, Véniant M, Latvala RD, Hirano KI, Won WB, Ross J, Dybdal N, Zlot CH, Young SG, Davidson NO.

Nat Med. 1998 Aug;4(8):934-8. Erratum in: Nat Med 1998 Oct;4(10):1200.

PMID:
9701246
11.

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF.

Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Review.

PMID:
23932550
12.

Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.

Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M.

J Am Coll Cardiol. 2013 Dec 10;62(23):2178-84. doi: 10.1016/j.jacc.2013.07.081. Epub 2013 Sep 4.

15.

Lipoprotein Lp(a) in homozygous familial hypercholesterolemia: density profile, particle heterogeneity and apolipoprotein(a) phenotype.

Guo HC, Chapman MJ, Bruckert E, Farriaux JP, De Gennes JL.

Atherosclerosis. 1991 Jan;86(1):69-83.

PMID:
1829609
16.

In vivo metabolism of ApoB, ApoA-I, and VLDL triglycerides in a form of hypobetalipoproteinemia not linked to the ApoB gene.

Elias N, Patterson BW, Schonfeld G.

Arterioscler Thromb Vasc Biol. 2000 May;20(5):1309-15.

PMID:
10807747
17.

Gene transfer of cytidine deaminase apoBEC-1 lowers lipoprotein(a) in transgenic mice and induces apolipoprotein B editing in rabbits.

Hughes SD, Rouy D, Navaratnam N, Scott J, Rubin EM.

Hum Gene Ther. 1996 Jan;7(1):39-49.

PMID:
8825867
18.

Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation.

Tremblay AJ, Lamarche B, Ruel IL, Hogue JC, Bergeron J, Gagné C, Couture P.

J Lipid Res. 2004 May;45(5):866-72. Epub 2004 Feb 16.

20.

Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.

Toth PP.

J Clin Lipidol. 2013 May-Jun;7(3 Suppl):S6-10. doi: 10.1016/j.jacl.2013.02.004. Epub 2013 Mar 27.

Supplemental Content

Support Center